Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Brigida Anna Maiorano; Martina Catalano; Evaristo Maiello; Giandomenico Roviello

doi:10.3389/fonc.2023.1254906

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Front Oncol. 2023 Sep 13:13:1254906. doi: 10.3389/fonc.2023.1254906. eCollection 2023.

Authors

Brigida Anna Maiorano¹, Martina Catalano², Evaristo Maiello¹, Giandomenico Roviello²

Affiliations

¹ Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
² Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

Abstract

Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC.

Keywords: ADC; antibody-drug conjugate; bladder cancer; enfortumab vedotin; nectin-4; urothelial carcinoma.

Publication types

Review